News

Aurobindo Pharma's biosimilar for breast cancer recommended for EU approval, demonstrating similarity to Herceptin.
Biocon Biologics Ltd receives positive CHMP opinions for denosumab biosimilars Vevzuo and Denosumab BBL, advancing bone ...
Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd, has announced ...
Hyderabad: CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma Limited, has announced that the ...
Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...
Besides generics, Dr. Reddy’s has committed a lot of resources to develop its biosimilars as well as new chemical entity business. Biosimilars have been seen as a growth engine for large, capable ...
The first wave of Stelara (ustekinumab) biosimilars show steep Wholesale Acquisition Cost discounts greater than 80%, the ...
China’s physicians expressed the highest support amongst surveyed countries. Physician attitudes toward patient involvement ...
Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost ...
Biocon Biologics had inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar ...
Prescription drugs continue to be the fastest-rising cost to many employer-sponsored health plans. A major driver of those ...
A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the ...